NEWCASTLE UPON TYNE, England and FLORENCE, Italy, Nov. 2, 2022 /PRNewswire/ — QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of point-of-need transformational molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), are pleased to announce an exclusive distribution agreement for QuantuMDx’s Q-POC™ platform in the UK and France.
Under the terms of the agreement, Menarini will market, sell and service QuantuMDx’s Q-POC™ SARS-CoV-2 assay and its new SARS-CoV-2, Flu A/B, RSV Respiratory Panel test that the company launched at the beginning of this year. The [five-year] deal will initially cover distribution to the UK and France, with the possibility of expanding to other markets.
Jonathan O’Halloran, CEO of QuantuMDx, said: “This agreement with Menarini is a significant business step for QuantuMDx. Menarini not only has an extensive global network, but also its country-specific knowledge and presence throughout Europe and beyond. there, means they are an excellent partner for us.The deal will allow us to further accelerate commercial sales of Q-POC™, bringing our Point-of-Need multiplex molecular diagnostics platform to clinical and non-clinical settings in a number of new markets. I look forward to working closely with Menarini on what I am sure will be a very successful partnership.”
Fabio Piazzalunga, Global Director of Menarini Diagnostics S.r.I., commented: “The recent pandemic has highlighted the importance of being able to diagnose infectious diseases accurately and quickly. QuantuMDx’s Q-POC™ platform, which can provide results in approximately 30 minutes, will allow healthcare professionals make informed treatment decisions and reduce the risk of transmission. Menarini is a pioneer in decentralizing diagnostic routines and developed core competencies and technologies in doing so. We are excited to begin providing such an innovative platform to laboratories in the UK and France”.
About QuantuMDx
QuantuMDx is a progressive medical technology company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the point of need.
QuantuMDx has global operations and strategic partnerships, keeping it at the forefront of molecular diagnostics.
Q-POC™ is a fast, easy-to-use and portable sample-to-response multiplex PCR device. It has been designed for use in a variety of real-world healthcare settings.
Q-POC™ and its first test, a multiplex SARS-CoV-2 detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), allowing use within the Union European and UK. On May 26, Q-POC received the CE mark under the IVDR (EU Regulation 2017/746).
QuantuMDx plans to launch a range of syndromic multiplex testing assays in the coming months and years.
For more information on QuantuMDx and Q-POC™, its rapid point-of-care PCR system, visit: www.quantumdx.com.
About A.Menarini Diagnostics, the human touch of technology:
The company has been dedicated to helping healthcare professionals make safe and sustainable diagnoses for more than 45 years, improving the quality of life for people around the world.
A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries around the world, has more than 17,000 employees and has a turnover in 2021 of 3,922 million euros.
More information at: www.menarinidiagnostics.com.
logo – link
View original content to download multimedia: enlace
